Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
General19 hours agoOsborne Park Football Club suspended for two years after Stephen Hawking costume controversy
-
General21 hours agoMelbourne Cup five quick hits: Melham magic, Blake Shinn falls, and concern over blood from Half Yours’s mouth
-
Noosa News22 hours agoFatal traffic crash, Cooloola Cove
-
General18 hours agoAustralia warned of assassination attempts by regimes